We’re excited to share that our latest episode of Ulysses Neuro Podcast is now online on all platforms! In this new episode of the Ulysses Neuro Podcast we spoke with Audrey, Maria and Matty.

Ulysses Neuroscience Ltd. is excited to announce that we are presenting at the CDKL5 Asia Conference that will take place in Tokyo on the next 21-22nd of September!

@kealyj @RCSI_Irl We are delighted to have the meeting back in person too! 2 days of great neuroscience ahead!

Delighted to be back in person at @NeuroscienceIRL which is being held at @RCSI_Irl this year.

Follow CDKL5 Columbia on Facebook https://t.co/UEWrPmaxTZ and Instagram https://t.co/ofnHE0Zt6B and follow @cdkl5spain on Facebook https://t.co/Z8YGoSYuhZ and Instagram https://t.co/W4x3xMNpVu #CDKL5Awareness #ThinkRare

To learn more about our previous and ongoing biomarker research in CDD, visit https://t.co/L6LkgXZCPZ or contact Carolina De Pasquale, our Patient Insight Manager and Clinical Lead, at carol.depasquale@ulysses-neuro.com.

June is International CDKL5 Awareness Month. CDKL5 Deficiency Disorder (CDD) is a rare neurodevelopmental disorder with an incidence rate of 1:40,000 - 1:60,000. Here, we share a message from Columbian mother Lisbet about her daughter Ruth Sofia, who has CDD.

The latest Ulysses Neuro Podcast episode is now live! In this episode, we speak with Crystal McLoughlin to discuss life with her 3 year old son Tomás, who has Angelman Syndrome.

For CDKL5 Deficiency Disorder and Dravet Syndrome Awareness month, CDKL5Brasil and DravetBrasil are partnering up for an online event: the Brazilian DEEs Symposium, on June 17th. The event will be live-streamed on their YouTube channel: https://t.co/TGwwugNpN1

As the Ulysses Neuroscience team continues to grow, join us in celebrating the promotion of Mary Glass to In-Vivo Operations Lead and the promotion of Laís Oliveira Lima to Office Manager / PA to the CEO.

PhD candidate and Ulysses Neuroscience Research Intern @fabiana_traini has begun analysing the first data following the successful start of our new clinical study, Syrens.

I’m delighted to have Claudia join us at Ulysses Maynooth!

May is Mental Health Awareness Month in the US. This campaign aims to encourage open conversations, promote understanding & highlight the need for accessible supports. Listen back to our Mental Health Awareness podcast with Stephen McBride, the Director of Services for @Aware

Ulysses Neuroscience Ltd. would like to introduce our latest project, ‘Syrens: a neurolinguistic study to assess cognitive abilities and develop composite biomarkers in Fragile X Premutation Carriers’. #FXS #ThinkRare

Ulysses Neuroscience Ltd. were proud to attend the launch of the Child Health Research Excellence at Trinity College Dublin 2023 Brochure, which features some of our clinical studies on rare neurodevelopmental disorders.

A busy week in Boston - if you didn’t get to catch us while we were there, it’s never too late to schedule a call.

We are honoured! @TCINeuroscience

Our neuroimmunology capabilities at @UlyssesNeuro are being presented now by @mb470102 at NIDD2023.

We’re at the Neuroimmunology Drug Development Summit in Boston to share our expertise and learn from our colleagues in the industry. We’re also staying in Boston until the 2nd May and happy to meet anyone interested in working with us.

🛩️The team have landed in Boston for the Neuroimmunology Drug Development Summit! 🇺🇸 - Founder/President & CEO - Prof Massimiliano Bianchi - CSO & EEG expert – Dr John Kealy - Preclinical Biomarker Lead - Dr Johana Tello 🗓️ We will be in Boston until May 2nd.